Pink Sheet reporters and editors consider lessons and next steps after the first list of drugs subject to Medicare price negotiations was released (:34) and discuss Oncopeptides’ Pepaxto facing withdrawal under the US FDA’s new and potentially faster process (22:44). More On The Medicare Price Negotiation List From The Pink Sheet Litigation Against Medicare Price Negotiation Gains Four Potential New Plaintiffs: https://pink.pharmaintelligence.informa.com/PS148778/Litigation-Against-Medicare-Price-Negotiation-Gains-Four-Potential-New-Plaintiffs Medicare Negotiation List Surprises Highlight The Importance Of Current Spending Data: https://pink.pharmaintelligence.informa.com/PS148781/Medicare-Negotiation-List-Surprises-Highlight-The-Importance-Of-Current-Spending-Data Patent Cliff Likely Accelerated By Two Years For Most Drugs On Medicare Price Negotiation List: https://pink.pharmaintelligence.informa.com/PS148775/Patent-Cliff-Likely-Accelerated-By-Two-Years-For-Most-Drugs-On-Medicare-Price-Negotiation-List Price Negotiation Purgatory: Upcoming Biosimilars Couldn’t Keep Stelara, NovoLog Off The List: https://pink.pharmaintelligence.informa.com/PS148776/Price-Negotiation-Purgatory-Upcoming-Biosimilars-Couldnt-Keep-Stelara-NovoLog-Off-The-List Timetable For Medicare Price Negotiation Of The First 10 Drugs (And Beyond): https://pink.pharmaintelligence.informa.com/PS148760/Timetable-For-Medicare-Price-Negotiation-Of-The-First-10-Drugs-And-Beyond CMS Seeking Patient Comments On Negotiated Drugs Similar To US FDA’s PFDD Program: https://pink.pharmaintelligence.informa.com/PS148773/CMS-Seeking-Patient-Comments-On-Negotiated-Drugs-Similar-To-US-FDAs-PFDD-Program Big Rebates Already A Big Factor For Drugs On Medicare Negotiation List: https://pink.pharmaintelligence.informa.com/PS148774/Big-Rebates-Already-A-Big-Factor-For-Drugs-On-Medicare-Negotiation-List Price Negotiation And The GLP1 Class: Trulicity Lucky To Be A BLA: https://pink.pharmaintelligence.informa.com/PS148794/Price-Negotiation-And-The-GLP1-Class-Trulicity-Lucky-To-Be-A-BLA More On The Pepaxto Withdrawal From The Pink Sheet To Save Pepaxto, Oncopeptides Throws Shade At IMiD Use In Elderly Myeloma Patients: https://pink.pharmaintelligence.informa.com/PS148770/To-Save-Pepaxto-Oncopeptides-Throws-Shade-At-IMiD-Use-In-Elderly-Myeloma-Patients How Fast Is ‘Expedited’? Pepaxto To Show Speed Of New Withdrawal Process For Accelerated Approval Drugs: https://pink.pharmaintelligence.informa.com/PS148766/How-Fast-Is-Expedited-Pepaxto-To-Show-Speed-Of-New-Withdrawal-Process-For-Accelerated-Approval-Drugs FDA’s Pepaxto Decider: Peter Marks To Handle Oncopeptides’ Appeal Of Accelerated Approval Withdrawal: https://pink.pharmaintelligence.informa.com/PS148761/FDAs-Pepaxto-Decider-Peter-Marks-To-Handle-Oncopeptides-Appeal-Of-Accelerated-Approval-Withdrawal

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related